Research across Cancer
Related studies from across the Cancer family.
Trastuzumab deruxtecan and pyrotinib provide disease control in lung squamous cell carcinoma with ERBB2 mutation
New Treatment Strategy Shows Promise for Lung Squamous Cell Carcinoma
This case report describes a patient with stage IA2 lung squamous cell carcinoma and an ERBB2 exon 20 p.G776V mutation treated with trastuzu…
A new treatment plan using trastuzumab deruxtecan and pyrotinib showed promising results for a patient with a specific lung cancer mutation.
Transitioning from static TNM staging to a multidimensional, adaptive treatment model integrating genomics and immunology for HPV-associated OPSCC
Doctors are shifting from static staging to adaptive care for HPV throat cancer
This narrative review discusses the evolving management of HPV-associated oropharyngeal squamous cell carcinoma. The authors argue for trans…
Medical teams are moving away from old staging rules toward a new model that uses genomics and immunology for precise care.
Review of gynecologic malignancies highlights dormant tumor cells as a therapeutic target
Doctors find dormant cancer cells could help stop gynecologic cancer from coming back after treatment
This narrative review examines ovarian, cervical, endometrial, and uterine sarcoma cancers. The authors synthesize evidence regarding dorman…
A review shows that sleeping cancer cells might cause tumors to return. Targeting these hidden cells could help prevent recurrence in ovaria…
High tumour mutation burden improves overall survival in solid tumours treated with immune checkpoint inhibitors
High Mutation Counts May Predict Better Cancer Survival Outcomes
This systematic review and meta-analysis evaluated 5278 patients with solid tumours treated with immune checkpoint inhibitors or chemotherap…
High mutation counts in tumors may help predict who will survive longer when taking powerful immune-boosting cancer drugs
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
Meta-analysis finds blood biomarkers predict outcomes in anal cancer but need validation
Low blood counts and high inflammation may signal worse survival for anal cancer patients
This systematic review and meta-analysis of 3589 patients with anal squamous cell carcinoma found that elevated neutrophil-to-lymphocyte rat…
For patients with anal cancer, low hemoglobin and high inflammation markers linked to poorer survival in this analysis of nearly 3,600 peopl…
Deep hyperthermia with tislelizumab and chemotherapy in advanced squamous NSCLC
Deep Heat Plus Drug Boosts Lung Cancer Response Rates
This retrospective cohort study of 100 patients with advanced squamous NSCLC evaluated deep hyperthermia combined with tislelizumab and chem…
Adding deep heat to standard lung cancer treatment improved response rates significantly while keeping safety levels the same as standard ch…
Disease progression and death in a 10 year old male with lower esophageal squamous cell carcinoma
Rare case: child dies 7 months after esophageal cancer diagnosis
This case report and retrospective literature analysis describes a 10 year old male with lower esophageal squamous cell carcinoma.
A 10-year-old with a rare esophageal cancer died 7 months after diagnosis, highlighting the urgent need for better treatments.
Retrospective review finds higher ORR with salvage DCRT in locally advanced ESCC
Salvage therapy works better than upfront treatment for some esophageal cancer patients
This retrospective analysis of 91 patients from 3 medical centers compared salvage versus upfront definitive chemoradiotherapy (DCRT) for lo…
New data shows treating esophageal cancer after a failed first attempt may lead to better outcomes than starting with the strongest drugs im…
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Nomogram predicts survival in uterine serous carcinoma using SEER and hospital data
New Tool Helps Doctors Predict Uterine Cancer Survival
This retrospective cohort study of 8,204 patients with uterine serous carcinoma developed a nomogram for overall survival prediction.
A new computer model helps doctors give honest survival estimates for patients with a deadly form of uterine cancer.
Case report details long-term survival in appendiceal signet-ring cell carcinoma with uterine involvement
A rare cancer found in the uterus and ovaries may be treated with surgery and chemo for over five years
This case report describes a 45-year-old woman with signet-ring cell carcinoma of the appendix involving the uterus and ovaries.
A rare cancer starting in the appendix showed up in the uterus and ovaries. Treatment with surgery and drugs helped a woman survive past fiv…